FY2025 EPS Estimates for Tilray Raised by Atb Cap Markets

Tilray Inc (NASDAQ:TLRY) – Analysts at Atb Cap Markets boosted their FY2025 earnings per share (EPS) estimates for shares of Tilray in a research report issued to clients and investors on Monday, December 16th. Atb Cap Markets analyst F. Gomes now anticipates that the company will earn ($0.13) per share for the year, up from their prior forecast of ($0.14). The consensus estimate for Tilray’s current full-year earnings is ($0.14) per share. Atb Cap Markets also issued estimates for Tilray’s FY2026 earnings at ($0.11) EPS, FY2027 earnings at ($0.04) EPS and FY2029 earnings at $0.05 EPS.

Tilray (NASDAQ:TLRY) last posted its quarterly earnings results on Thursday, October 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). Tilray had a negative net margin of 26.79% and a negative return on equity of 2.00%. The firm had revenue of $200.00 million for the quarter, compared to analyst estimates of $218.70 million. During the same period in the prior year, the firm posted ($0.10) earnings per share. The company’s quarterly revenue was up 13.0% compared to the same quarter last year.

Separately, Roth Mkm lowered their price target on Tilray from $2.00 to $1.75 and set a “neutral” rating on the stock in a research report on Friday, October 11th.

Tilray Price Performance

Shares of TLRY stock opened at $1.16 on Thursday. Tilray has a 52-week low of $1.15 and a 52-week high of $2.97. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -4.30 and a beta of 2.08. The firm’s 50-day moving average is $1.45 and its 200-day moving average is $1.66. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.57 and a current ratio of 2.47.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TLRY. Ferguson Wellman Capital Management Inc. acquired a new position in shares of Tilray during the 3rd quarter worth approximately $26,000. Signature Estate & Investment Advisors LLC bought a new position in Tilray during the 2nd quarter worth $29,000. Jeppson Wealth Management LLC acquired a new position in Tilray in the 2nd quarter valued at $33,000. Vanguard Capital Wealth Advisors acquired a new position in Tilray in the 2nd quarter valued at $34,000. Finally, Pallas Capital Advisors LLC bought a new stake in shares of Tilray during the 2nd quarter valued at $37,000. 9.35% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Tilray

In other news, CFO Carl A. Merton bought 26,000 shares of the firm’s stock in a transaction dated Friday, November 15th. The shares were bought at an average price of $1.36 per share, with a total value of $35,360.00. Following the completion of the transaction, the chief financial officer now owns 26,000 shares of the company’s stock, valued at $35,360. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.87% of the stock is currently owned by corporate insiders.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.